Brazil approves Sun Pharma's generic semaglutide injection for type 2 diabetes

Brazil's health regulator, ANVISA, has approved Sun Pharmaceutical Industries to manufacture and market semaglutide injections for adults with inadequately controlled type 2 diabetes, the company said. Sun plans to launch the product in the next few days through a partnership with Brazil-based Hypera Pharma ^[1].

The medicine will be sold as a pre-filled, multi-dose injectable pen in two strengths — 2 mg/1.5 mL and 4 mg/3 mL — for once-weekly administration ^[1]. Semaglutide is the molecule sold in the United States as Ozempic, Wegovy and Rybelsus. The Brazilian approval covers type 2 diabetes treatment, not weight management ^[1].

Sun cited IQVIA data showing Brazil's semaglutide injectable market was valued at about $413 million for the 12 months ended June 2026 ^[1].

Aalok Shanghvi, Sun Pharma's chief operating officer, said, "The approval of semaglutide in Brazil expands access to an evidence-based treatment option for people living with inadequately controlled type 2 diabetes. It reflects the strength of our development and manufacturing capabilities and our commitment to delivering high-quality medicines across global markets" ^[1].

Digvijay Singh, the company's regional head for Brazil and Latin America, said the approval would strengthen Sun's diabetes portfolio in the country and help expand patient access through the local partnership ^[1].

The clearance comes months after key semaglutide patent expiries opened the market to generic competition in several countries ^[1]. ANVISA has recently approved multiple semaglutide products, and Sandoz also received marketing authorization for its semaglutide product, Owozy, developed with Adalvo ^[1].

Sun did not disclose a price for the Brazilian product. The report did not say how much of the $413 million market the company expects to capture, and no launch date beyond "the next few days" was given ^[1].

Why it matters for patients

For readers in the United States, this approval does not change what is on US pharmacy shelves. Drug approvals are country by country, and the US Food and Drug Administration makes its own decisions about which products may be sold here. Brazil's ANVISA signing off on a generic semaglutide injection is a signal that copycat versions are spreading as patents lapse, but it is not a US approval.

Sun Pharma has not said whether it will seek US approval for this product, and no such filing has been reported ^[1]. The company also has not disclosed pricing in Brazil, so it is not yet known how much patients there would pay or how the launch might affect prices from other manufacturers in that market ^[1].

Because the Brazilian approval is limited to type 2 diabetes, it does not establish that this product will be sold for weight loss in Brazil ^[1]. Whether semaglutide copies approved for diabetes are also used for weight management in Brazil is a separate question of prescribing and regulation that this approval does not address.

In the US, Ozempic, Wegovy and Rybelsus remain brand-name products made by Novo Nordisk, and no generic semaglutide has been reported as approved for the US market in this development. Separately, tirzepatide is sold as Mounjaro and Zepbound, and orforglipron is sold as Foundayo; those are different molecules and are not affected by this approval ^[1].

What happens next

Sun said the launch would happen "in the next few days" through Hypera Pharma, according to a company announcement dated July 30, 2026 ^[1].

The Brazilian market is already competitive. ANVISA has cleared several semaglutide products following patent expiries, including Sandoz's Owozy ^[1]. No timeline has been reported for additional approvals in Brazil or for any application in the United States.